047920.KQ HLB Pharmaceutical Co. Ltd
- Market cap
- KRW 414B
- P/E
- 150.3x
- P/B
- 3.16x
- ROE
- 1.0%
- Dividend yield
- -
- Fundamental score
- 1.1/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 047920.KQ undervalued?
Graham numberThe Graham number of HLB Pharmaceutical Co. Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
HLB Pharmaceutical Co. Ltd fundamental analysis
5 of 22 checks passedROE 0/2
Low return on equity (1.0%), below 10%.
ROA 0/1
Return on assets (0.7%) is below the industry median (1.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (92.8%) is above the industry median (1.8%).
Revenue Growth 2/2
Revenue grew 24.1% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Debt is not reported.
Interest Coverage 0/1
EBIT is 3.1x against interest expense, below 5x.
PE vs Market 0/1
PE (150.3x) is above the market median (11.3x).
PE vs Industry 0/1
PE (150.3x) is above the industry median (11.4x).
PBV 0/1
Price to book (3.2x) is above the industry median (0.9x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 475.5, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
HLB Pharmaceutical Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About HLB Pharmaceutical Co. Ltd
HLB Pharmaceutical Co., Ltd. researches and develops peptide drugs in South Korea. The company offers skeletal muscle relaxant, tranquilizers, antihistamines, antihypertensive agents, pain relief, antipruritics, astringents, anti-inflammatories, alimentary system drugs, metabolic drugs, ophthalmic agents, local anesthetics, antiarteriosclerotic agents, expectorants, antipyretics, analgesics, antidiabetic drug, chemotherapeutics, peptic ulcer agents, central nervous system dr…
Full company profileHLB Pharmaceutical Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
HLB Pharmaceutical Co. Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 20.3B | 15.6B | 20.5B | 36.1B | 40.6B | 62.9B | 107B | 136B | 137B | 206B | 256B |
| Gross Profit | 5.49B | 2.80B | 4.47B | 18.0B | 22.3B | 35.4B | 64.0B | 83.0B | 86.6B | 107B | 115B |
| Operating Income | 406M | -4.37B | -5.41B | 1.00B | -2.08B | 486M | -6.42B | -5.44B | -10.7B | 1.06B | 2.00B |
| EBITDA | - | - | - | - | - | - | -1.39B | -2.04B | 6.88B | 9.84B | 6.99B |
| Net Income | 577M | -5.45B | -7.06B | 473M | -74.8B | -13.2B | -11.8B | -19.4B | 2.02B | 4.57B | 1.33B |
| EPS | 49 | -436 | -510 | 34 | -3,565 | -507 | -423 | -641 | 67 | 128 | 37 |
| Balance Sheet | |||||||||||
| Total Assets | 41.2B | 39.8B | 36.4B | 46.4B | 111B | 128B | 142B | 141B | 158B | 171B | 178B |
| Total Liabilities | 22.3B | 23.0B | 19.4B | 29.0B | 66.8B | 49.2B | 56.2B | 53.2B | 41.5B | 45.5B | 47.3B |
| Shareholders' Equity | 18.9B | 16.8B | 17.0B | 17.4B | 44.6B | 78.4B | 85.9B | 88.2B | 116B | 125B | 131B |
| Cash & Short-term Investments | 11.9B | 11.0B | 9.11B | 14.0B | 79.3B | 25.5B | 24.6B | 25.9B | 10.5B | 7.61B | 4.51B |
| Total Debt | 13.7B | 4.57B | 2.61B | 4.73B | 4.32B | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -213M | -784M | -1.78B | 1.35B | -403M | -1.32B | -2.76B | -18.3B | 6.84B | 569M | 2.73B |
| Capital Expenditure | 4.77B | 2.24B | 1.10B | 1.40B | 2.98B | 49.5B | 2.90B | 4.26B | 3.09B | 7.21B | 7.74B |
| Free Cash Flow | - | - | - | - | -3.38B | -50.8B | -5.66B | -22.6B | 3.75B | -6.64B | -5.01B |
| Ratios | |||||||||||
| ROE | 3.1% | -32.4% | -41.5% | 2.7% | -167.7% | -16.9% | -13.7% | -22.0% | 1.7% | 3.7% | 1.0% |
| ROA | 1.4% | -13.7% | -19.4% | 1.0% | -67.2% | -10.4% | -8.3% | -13.7% | 1.3% | 2.7% | 0.7% |
| Net Profit Margin | 2.8% | -35.0% | -34.4% | 1.3% | -184.5% | -21.0% | -11.0% | -14.3% | 1.5% | 2.2% | 0.5% |
| Debt to Equity | 0.73x | 0.27x | 0.15x | 0.27x | 0.10x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
HLB Pharmaceutical Co. Ltd dividends
HLB Pharmaceutical Co. Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 1.5:1 on Apr 12, 2016.
Who owns HLB Pharmaceutical Co. Ltd
- Insiders 15.76%
- Institutions 0.50%
- Public & others 83.73%
- Shares outstanding 43.6M
- Free float 24.8M
HLB Pharmaceutical Co. Ltd company profile
- Company name
- HLB Pharmaceutical Co. Ltd
- Ticker
- 047920.KQ
- ISIN
- KR7047920004
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 197
- Fiscal year end
- December
- Address
- 27, Gyeonggang-ro, Namyangju-si, South Korea, 12244
- Phone
- 82 3 1557 0001
- Website
- hlbpharma.co.kr
About HLB Pharmaceutical Co. Ltd
HLB Pharmaceutical Co., Ltd. researches and develops peptide drugs in South Korea. The company offers skeletal muscle relaxant, tranquilizers, antihistamines, antihypertensive agents, pain relief, antipruritics, astringents, anti-inflammatories, alimentary system drugs, metabolic drugs, ophthalmic agents, local anesthetics, antiarteriosclerotic agents, expectorants, antipyretics, analgesics, antidiabetic drug, chemotherapeutics, peptic ulcer agents, central nervous system drug, antibiotics, digestives, antacids, dental drugs, multivitamins, parasistic skin disese drugs, dermatlogicals, agents for urogenital organ, amino acid agent, antitussive, mucolytic agents, anthelmintics, antidiarrheals, circulatory system drug, vitamins, skin softeners, anti-hemorrhoid drugs, and agents for liver disease. It is also developing CTT-004 for the treatment of ataxia induced by spinocerebellar degeneration; and offers CMO services. The company was formerly known as Mediforum Pharmaceutical Incorporation and changed its name to HLB Pharmaceutical Co., Ltd in October 2020. HLB Pharmaceutical Co., Ltd. was founded in 1998 and is headquartered in Namyangju-si, South Korea.
HLB Pharmaceutical Co. Ltd management
3- Mr. Jae-Hyung ParkCEO & Executive Director · born 1966
- Mr. Kyung-Won ParkDirector of Sales · born 1978
- Mr. Man-Gyu KimVP of Strategic Planning & Executive Director · born 1975